Fortress Biotech Inc. (NASDAQ:FBIO)’s share price traded down 4.3% on Monday . The company traded as low as $2.88 and last traded at $2.90, with a volume of 116,557 shares traded. The stock had previously closed at $3.03.

Separately, FBR & Co restated an “outperform” rating on shares of Fortress Biotech in a research report on Wednesday, July 20th.

The firm’s market cap is $140.70 million. The firm has a 50-day moving average price of $2.81 and a 200-day moving average price of $2.97.

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Fortress Biotech Inc. will post ($1.23) EPS for the current fiscal year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.